NHMRC Postdoctoral Research Officer
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Dr Daniel Barratt is a mid career researcher in the Neuroimmunopharmacology Lab of Prof Mark Hutchinson (Discipline of Physiology) and member of the Clinical Pharmacogenomics and Drug Disposition Lab in the Discipline of Pharmacology. He is also a member of the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP).
Dr Barratt has over 15 years of research experience in the area called "pharmacogenetics" or more commonly now, "pharmacogenomics"; determining how our genes influence our individual responses to drugs, and how this can be used to better personalise treatments for improved safety and efficacy.
My current research focuses on identifying predictors and biomarkers of acute and chronic pain, analgesic response, and physical and psychological performance and resilience, in humans and livestock.
I have an extensive research background in clinical pharmacogenomics (especially opioid analgesics) and the neuroimmunogenetics of pain. In addition, I have led research integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers, for the personalised dosing of tyrosine kinase inhibitors against cancer. I have also been working collaboratively to identify common drug-related genetic variants in Aboriginal Australians to guide recommendations for personalised prescribing, on clinical pharmacology and pharmacogenetics research to guide precision medicine approaches in organ transplant, and on the clinical pharmacokinetics and pharmacogenetics of infectious disease treatments in Papua New Guinea.
Current Research Projects
- "Biomarkers of persistent pain in livestock": Translating human biomarkers of pain into the livestock setting to predict the chronic pain of animal husbandry practices.
- “A novel pathway to reduce the burden of chronic pain”: Determining how neuroimmune signalling pathway (NSP) (epi)genetics influence chronic postsurgical pain and establishing an improved framework for developing personalised pain treatment based on NSP biomarkers.
- “Biomarker determinants of ketamine efficacy”: Determining pharmacokinetic and genomic determinants of ketamine efficacy in chronic pain and treatment-resistant depression.
- “Improving the treatment of breathlessness”: Determining genetic predictors of the efficacy of sustained-release morphine in chronic refractory breathlessness.
- “Personalised medicines for Aboriginal people”: Identifying and comparing drug-related genetic variation in Aboriginal and non-Aboriginal Australians, to ultimately guide personalised prescribing in Aboriginal people.
- “Pharmacogenomics of mercaptopurine toxicity among paediatric ALL patients”: Determining the relationship between NUDT15 genetic deficiency and thiopurine toxicity in Aboriginal children with acute lymphoblastic leukaemia and lymphoma, and establishing a NUDT15 sequencing protocol for clinical implementation.
- “Clinical pharmacology of infectious disease treatments in Papua New Guinea”: Identifying pharmacokinetic and genomic determinants of treatment response to enable drug therapy optimization for the PNG population.
- “The inside story on variable tyrosine kinase inhibitor response and toxicity”: Integrating clinical and experimental pharmacokinetics, pharmacogenomics and mechanisms of drug resistance, for the personalised dosing of tyrosine kinase inhibitors (TKI).
Date Position Institution name 2020 - 2023 Internal Grant-Funded Researcher B University of Adelaide 2015 - 2019 NHMRC Postdoctoral Research Officer University of Adelaide 2011 - 2014 Research Assistant University of Adelaide
Date Institution name Country Title — University of Adelaide Australia PhD — University of Adelaide Australia BSc (Hons)
Year Citation 2016 Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger.
Year Citation 2016 Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.
Dr Barratt teaches within the B.HlthMedSci program.
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2019 Co-Supervisor Infectious diseases pharmacokinetics Doctor of Philosophy Doctorate Full Time Ms Natalia Bordin Andriguetti 2018 Co-Supervisor Pharmacogenomics in Indigenous Populations Doctor of Philosophy Doctorate Full Time Miss Helena Katherina Van Schalkwyk
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2016 - 2019 Co-Supervisor Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes Doctor of Philosophy Doctorate Full Time Ms Rong Hu 2014 - 2015 Co-Supervisor Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib Master of Philosophy (Medical Science) Master Full Time Mr Muhammad Suleman Khan
Date Role Committee Institution Country 2016 - ongoing Member Adelaide Medical School Health Safety and Welfare Committee — — 2013 - ongoing Member ASCEPT Scientific Advisory Committee — — 2013 - ongoing Vice-Chair ASCEPT Pharmacogenomics Special Interest Group — —
Date Role Membership Country 2020 - ongoing Member International Association for the Study of Pain United States 2019 - ongoing Member Australasian Neuroscience Society Australia 2005 - ongoing Member Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists —
Connect With Me